


[Fig. 1]




[Fig. 2]




[Fig. 3]


A
B
MPH-A24-9-278 #5-2
MPH-A24-9-278 #22
MPH-A24-9-278 #49
MPH-A24-9-278 #51
MPH-10-278 #15
IFN γ (pg/ml)
R/S ratio
4000
3000
2000
1000
0
−1000
5000
400
300
200
100
40 20 10 5 2.5 1.3 0.6 0.3
+
−


[Fig. 4]


MPH
HLA+MPH
HLA
MPH-A24-9-278 clone#49, #5-2 endo
IFN-γ (pg/ml)
300
250
200
150
100
50
0
×5
×2.5
×1.2
×0.6
R/S ratio


[Fig. 5]


MPH-A24-9-278
HT1376
J82
RT-4
IFN-γ (pg/ml)
80
70
60
50
40
30
20
10
0
2.5
1.2
0.6
R/S ratio


[Fig. 6]


R/S=20
R/S=5
R/S=1
SFC
80
60
40
20
0
Ani 1
Ani 2
Ani 3
Ani 4
Ani 5
nega 1
nega 2
nega 3


[Fig. 7]




[Fig. 8]


A
MPH-A02-9-282 #5
IFN-g (pg/ml)
5000
4000
3000
2000
1000
0
−1000
40 20 10 5 2.5 1.25 0.63 0.32
R/S ratio
+
−
B
MPH-A02-9-638 #8
IFN-g (pg/ml)
800
600
400
200
0
−200
40 20 10 5 2.5 1.25 0.63 0.32
R/S ratio
+
−
C
MPH-A02-10-1714 #4
IFN-g (pg/ml)
1000
800
600
400
200
0
40 20 10 5 2.5 1.2 0.6 0.3
R/S ratio
+
−


[Fig. 9]


A
Peptide
+ − + − + − + − + − + −
A
B
C
D
E
F
G
H
B
C.T.L.
MPH-A02-9-282 clone #81
IFN-γ (pg/ml)
3000
2000
1000
0
−1000
R/S ratio
10 5 2.5 1.3 0.6 0.3 0.15 0.075
MPH-A02-9-282 clone #50
IFN-γ (pg/ml)
3000
2000
1000
0
−1000
R/S ratio
10 5 2.5 1.3 0.6 0.3 0.15 0.075


[Fig. 10]


A
DEPDC1-A24-9-294
+
−
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C.T.L. Cellular Technology Ltd.
B
Peptide
+ − + − + − + − + − + −
A B C D E F G H
C.T.L.


[Fig. 11]


DEPDC1-A24-9-294 #10
DEPDC1-A24-9-294 #48
DEPDC1-A24-9-294 #8
DEPDC1-A24-9-294 #42
IFN γ (pg/ml)
R/S ratio
+
−
4000
3000
2000
1000
0
−1000
5000
40
20
10
5
2.5
1.3
0.6
0.3


[Fig. 12]


DEPDC1-A24-9-294 clone #8 endo
DEP
HLA+DEP
HLA
IFN-γ (pg/ml)
120
100
80
60
40
20
0
×5
×2.5
×1.2
×0.6
R/S ratio
DEP: DEPDC1


[Fig. 13]


DEPDC1-A24-9-294
HT1376
J82
RT-4
IFN-γ (pg/ml)
50
40
30
20
10
0
2.5
1.2
0.6
R/S ratio


[Fig. 14]


R/S=40
R/S=10
R/S=2
SFC
200
180
160
140
120
100
80
60
40
20
0
Ani 1
Ani 2
Ani 3
Ani 4
Ani 5
nega 1
nega 2


[Fig. 15]


DEPDC1-A02
-10-301
DEPDC1-A02
-10-296
DEPDC1-A02
-9-297
DEPDC1-A02
-10-224
DEPDC1-A02
-10-395
DEPDC1-A02
-10-765
DEPDC1-A02
-10-506
DEPDC1-A02
-10-575
DEPDC1-A02
-10-644
−
+
Peptide
1
2
3
4
5
6
7
8


[Fig. 16]


DEPDC1-A02-10-296 #4
IFN-γ (pg/ml)
3000
2500
2000
1500
1000
500
0
5
2.5
1.25
0.63
0.31
0.16
0.08
0.04
R/S ratio
+
−
DEPDC1-A02-9-653 #1
IFN γ (pg/ml)
7500
6000
4500
3000
1500
0
+20
+10
+5
+2.5
+1.25
+0.6
R/S ratio
+
−


[Fig. 17]


Hek-A02 DEPDC1V1-9-674 pep
Hek-A02 DEPDC1V2
Hek-Mock DEPDC1V2
IFN γ (pg/ml)
R/S ratio
16
14
12
10
8
6
4
2
0
9
4.5
2.2
1.1
0.6
0.3
Hek293 DEP-A02-9-653
A02/DEP
A02/DEP-9-462 pep
DEP
IFN γ (pg/ml)
R/S ratio
35
30
25
20
15
10
5
0
1.5
0.7
0.3
0.15
0.07
0.03


[Fig. 18]




[Fig. 19]


Bladder
23 mm
After Vaccination
Bladder
24 mm
Before Vaccination


[Fig. 20]




[Fig. 21]


2006.12.12
2007.02.06
2007.05.08
2007.06.04
2007.07.06
2007.08.04
Before
After 1 co.
After 2 co.
After 3 co.
2006.12.12
2007.02.06
2007.05.08
2007.06.04
2007.07.06
2007.08.04
Before
After 1 co.
After 2 co.
After 3 co.


[Fig. 22]


2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.
2006.12.12
2007.02.06
2007.05.08
Before
2007.06.04
After 1 co.
2007.07.06
After 2 co.
2007.08.04
After 3 co.


[Fig. 23]


Vaccination
06.12.12
07.02.06
07.05.08
07.06.04
07.07.06
07.08.10
250
200
150
100
RECIST Sum

[Fig. 24]


Specific spots = Spots(DEPDC1 pep) – Spots(HIV pep)
Before
After 1course
After 2 course
0
10
20
30
Specific spots

[Fig. 25]



[Fig. 26]

